Immuneering Corporation

NASDAQ•IMRX

CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-07-30

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

連絡先情報

245 Main Street, Second Floor, Cambridge, MA, 02142, United States

617-500-8080

immuneering.com

時価総額

$193.49M

PER (TTM)

-6.1

18.8

配当利回り

52週高値

$10.08

52週安値

$1.10

52週レンジ

47%

順位44Top 53.8%

3.7

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 3.7 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.18+0.00%

直近4四半期の推移

フリーCF

$0.00+0.00%

直近4四半期の推移

2026 Annual 決算ハイライト

主なハイライト

Net Loss Decreased Net loss $56.0M for 2025, an 8.2% reduction compared to $61.0M loss reported in 2024.

R&D Spending Reduced Total R&D expenses fell 12.3% to $42.0M in 2025, driven by pausing envometinib program development efforts.

Significant Capital Raised Financing activities provided $226.6M cash, reflecting multiple private placements and public equity offerings during 2025.

Cash Runway Extended Cash reserves $128.6M as of year-end, sufficient to fund operations and development activities into 2029.

リスク要因

Late-Stage Clinical Dependency Business substantially dependent on successful atebimetinib development; no products approved for commercial sale currently.

Substantial Capital Needs Requires substantial additional capital to finance operations; failure to raise funds delays or eliminates development programs.

Regulatory Approval Unpredictable Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable regarding outcomes for candidates.

Platform Technology Reliance Business substantially dependent on proprietary platform and information technology systems; failure materially harms operations.

見通し

Phase 3 Trial Dosing Planned Expect dosing first patient in atebimetinib Phase 3 MAPKeeper 301 trial in mid-2026 for pancreatic cancer indication.

Atebimetinib Data Updates Announce further updated survival data from over 50 first-line pancreatic cancer patients in first half of 2026.

New Combination Trial Dosing Dosing first patient in planned atebimetinib combination trial with Libtayo in NSCLC patients second half 2026.

Envometinib Partnership Focus Paused internal advancement of envometinib; pursuing partnership opportunities and considering other developmental paths.

同業比較

売上高 (TTM)

ARCT

$67.22M

-51.4%

ENTA

$66.98M

+0.6%

CDXS

$52.93M

-17.9%

粗利益率 (最新四半期)

ENTA

100.0%

+0.0pp

ASMB

100.0%

+0.0pp

SGMO

100.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
SLS	$787.70M	-23.1	-95.2%	1.2%
TRDA	$480.80M	-3.6	-39.8%	13.5%
ASMB	$447.15M	-5.6	-59.0%	1.1%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月19日

EPS:-$0.31

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし